We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PharmaDiagnostics is Granted US Patent for Nanoparticle-Conductive Polymer Technology

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
PharmaDiagnostics NV announces that it has been granted a US patent covering its nanoparticle/conductive polymer composites. The patent is entitled "Stable metal/conductive polymer composite colloids and methods for making and using the same".

The company has discovered that, by coating its nanoparticles with a conductive polymer, the inherent sensitivity is increased. This coating enhances the interaction of photons with the electrons on the particles' surface, thus increasing the signal generated when a molecule interacts with the composite. The composites are sensitive to the redox state of the interacting molecules, a physical property of a molecule that is important but often overlooked in the discovery process. The Company uses the technology in its redox potential assay which allows high throughput measurement of redox potential on standard laboratory equipment

Label-free screening is currently an area of great interest in the market. PharmaDiagnostics' approach stands out as all other available label-free technologies require expensive dedicated equipment which restricts both breadth of application and compound throughput.

PharmaDiagnostics' localized surface plasmon resonance technology (LSPR) is broadly enabling, with easy to use protocols, and is applicable to a range of assays for both small molecule and antibody screening and characterization. For the first time, label-free screening can be applied in high throughput applications.

"The grant of this US patent is clear recognition of the innovative nature and industrial applicability of PharmaDiagnostics' technology platform," said Dr David Ricketts, CEO at PharmaDiagnostics. "It is a key step forward for us and will enable us to maximize the commercial potential of our screening technology."